Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study

Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study

Yong Wang, Xiangji Meng, Shizhen Zhou, Yufang Zhu, Jun Xu, Rongjie Tao Department of Neurosurgery, Shandong Cancer Hospital Affiliated to Shandong University; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People’s...

Full description

Bibliographic Details
Main Authors: Wang Y, Meng X, Zhou S, Zhu Y, Xu J, Tao R
Format: Article
Language:English
Published: Dove Medical Press 2019-12-01
Series:OncoTargets and Therapy
Subjects:
central nervous system
recurrence
glioblastoma
apatinib
temozolomide
vascular endothelial growth factor receptor
Online Access:https://www.dovepress.com/apatinib-plus-temozolomide-for-recurrent-glioblastoma-an-uncontrolled--peer-reviewed-article-OTT

Internet

https://www.dovepress.com/apatinib-plus-temozolomide-for-recurrent-glioblastoma-an-uncontrolled--peer-reviewed-article-OTT

Similar Items